SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Files An 8-K Financial Statements and Exhibits

SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Files An 8-K Financial Statements and Exhibits

Story continues below

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
Exhibit No.
Description
10.1
License and Option Agreement, dated as of December 2,
2016, by and between Spark Therapeutics, Inc. and the
Company.
Certain information in this exhibit has been omitted
and filed separately with the Securities and Exchange
Commission to a confidential treatment request under 17
C.F.R. Sections 200.80(b)(4) and 24b-2.
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
SELECTA BIOSCIENCES, INC.
Date: February 14, 2017
By:
/s/ Werner Cautreels, Ph.D.
Werner Cautreels, Ph.D.
President and Chief Executive Officer
Exhibit Index
Exhibit No.
Description
10.1
License and Option Agreement, dated as of December 2,
2016, by and between Spark Therapeutics, Inc. and the
Company.
Certain information in this exhibit has been omitted
and filed separately with the Securities and Exchange
Commission


About SELECTA BIOSCIENCES, INC. (NASDAQ:SELB)

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The Company’s product candidates are in development. The Company’s SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s technology allows for the design of SVP therapies that can stimulate immune responses against a range of relevant antigens. Its initial immune-stimulating product candidate is a synthetic vaccine against nicotine for the market of smoking cessation and relapse prevention.

SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Recent Trading Information

SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) closed its last trading session down -0.02 at 14.03 with 72,593 shares trading hands.

An ad to help with our costs